AnaBios Corporation

AnaBios Corporation

AnaBios operates at the intersection of human tissue procurement and preclinical contract research. The firm sources healthy and diseased samples — heart, dorsal root ganglia, lung slices, brain tissue, and hepatocytes — through a network of hospitals and organ-procurement organizations. It then applies proprietary preservation methods and standardized ex-vivo platforms to generate efficacy and safety data that, according to the firm, regulatory bodies increasingly favor over animal models. CEO Andre Ghetti, CCO Chris Mathes, and CFO Charles Chesnutt direct a San Diego-based operation that runs Cardioprime cardiac assays, pain assays on dorsal root ganglion neurons, lung-slice fibrosis models, neurotoxicity testing, and kidney assays. AnaBios published a bioRxiv study co-authored with Cytokinetics that used human cardiomyocytes and engineered heart tissue to examine cardiac hypercontractility and heart failure with preserved ejection fraction (HFpEF). The firm also features a webinar with Harvard neurobiology professor Bruce Bean on Nav1.8 sodium-channel inhibition by suzetrigine (Journavx), a selective pain therapy. The firm's revenue derives from supplying human tissue and cells to pharmaceutical, biotech, and academic clients, alongside fee-for-service functional assays. In September 2023, AnaBios highlighted an FDA scientific review concluding that adult human primary tissue data more reliably predicts clinical cardiac outcomes than traditional models. Client-facing statements on the website frame AnaBios as a bridge between bench and clinic, aiming to cut development timelines and costs by eliminating molecules destined to fail in human studies. AnaBios’s structural distinction lies in its vertically integrated procurement-to-platform model: the firm controls the cold chain, donor-qualification logistics, assay development, and data generation in a single workflow. This design gives drug developers a human-derived readout at the lead-optimization stage, before regulatory animal toxicology becomes the development bottleneck. The firm does not disclose the size of its donor network or its commercial terms publicly.